Geode Capital Management LLC Grows Stock Holdings in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP)

Geode Capital Management LLC raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP - Free Report) by 4.2% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 425,225 shares of the specialty pharmaceutical company's stock after acquiring an additional 17,314 shares during the quarter. Geode Capital Management LLC owned approximately 2.02% of ANI Pharmaceuticals worth $25,373,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Texas Permanent School Fund Corp increased its position in shares of ANI Pharmaceuticals by 1.3% during the second quarter. Texas Permanent School Fund Corp now owns 13,372 shares of the specialty pharmaceutical company's stock worth $852,000 after purchasing an additional 178 shares in the last quarter. Louisiana State Employees Retirement System grew its holdings in shares of ANI Pharmaceuticals by 2.7% during the second quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company's stock worth $490,000 after buying an additional 200 shares in the last quarter. Arizona State Retirement System raised its position in shares of ANI Pharmaceuticals by 4.7% in the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company's stock valued at $299,000 after buying an additional 211 shares during the last quarter. Thrivent Financial for Lutherans lifted its stake in shares of ANI Pharmaceuticals by 2.3% in the third quarter. Thrivent Financial for Lutherans now owns 13,028 shares of the specialty pharmaceutical company's stock worth $777,000 after buying an additional 299 shares in the last quarter. Finally, New York State Teachers Retirement System boosted its position in ANI Pharmaceuticals by 1.7% during the third quarter. New York State Teachers Retirement System now owns 24,120 shares of the specialty pharmaceutical company's stock worth $1,439,000 after acquiring an additional 394 shares during the last quarter. Hedge funds and other institutional investors own 76.05% of the company's stock.

Insider Buying and Selling

In other news, CFO Stephen P. Carey sold 7,500 shares of the stock in a transaction that occurred on Tuesday, December 17th. The stock was sold at an average price of $55.79, for a total value of $418,425.00. Following the completion of the sale, the chief financial officer now directly owns 154,468 shares of the company's stock, valued at approximately $8,617,769.72. This represents a 4.63 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Krista Davis sold 1,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, December 11th. The shares were sold at an average price of $60.00, for a total transaction of $60,000.00. Following the completion of the transaction, the senior vice president now directly owns 49,059 shares in the company, valued at $2,943,540. The trade was a 2.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 42,231 shares of company stock worth $2,434,286 in the last ninety days. 12.70% of the stock is owned by corporate insiders.

ANI Pharmaceuticals Stock Down 2.0 %

Shares of ANI Pharmaceuticals stock traded down $1.09 during trading hours on Friday, reaching $54.41. 248,946 shares of the company were exchanged, compared to its average volume of 225,082. The firm has a market cap of $1.14 billion, a PE ratio of -98.93 and a beta of 0.73. The stock's fifty day moving average is $57.36 and its 200 day moving average is $59.60. ANI Pharmaceuticals, Inc. has a 1 year low of $52.50 and a 1 year high of $70.81. The company has a debt-to-equity ratio of 1.52, a quick ratio of 1.97 and a current ratio of 2.74.

ANI Pharmaceuticals (NASDAQ:ANIP - Get Free Report) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. The firm had revenue of $148.30 million during the quarter, compared to analysts' expectations of $144.37 million. ANI Pharmaceuticals had a positive return on equity of 15.87% and a negative net margin of 1.28%. The firm's revenue was up 12.5% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.05 earnings per share. As a group, equities research analysts forecast that ANI Pharmaceuticals, Inc. will post 3.87 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on ANIP. HC Wainwright reiterated a "buy" rating and issued a $94.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, November 11th. Leerink Partners initiated coverage on ANI Pharmaceuticals in a research report on Wednesday, December 11th. They set an "outperform" rating and a $80.00 price objective on the stock. Truist Financial upped their target price on ANI Pharmaceuticals from $60.00 to $62.00 and gave the company a "hold" rating in a report on Tuesday, October 22nd. Raymond James lifted their price target on ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an "outperform" rating in a report on Wednesday, September 18th. Finally, StockNews.com lowered shares of ANI Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Saturday, September 7th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $77.71.

About ANI Pharmaceuticals

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.